Can a new antibiotic outmatch an old one against Drug-Resistant pneumonia?
NCT ID NCT07759934
First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time
Summary
This trial is testing an experimental antibiotic called ASK0912 against an older drug, polymyxin B, in adults with hospital-acquired or ventilator-associated pneumonia caused by multidrug-resistant bacteria. Participants will receive one of two dosing schedules of ASK0912 or the standard polymyxin B treatment for 7 to 14 days. The study will compare how well each treatment clears the infection and whether it reduces deaths within 28 days, while also monitoring safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ASK0912 for injection
- What this could lead to
- If successful, this could provide a new treatment option for serious hospital-acquired pneumonia caused by drug-resistant bacteria, potentially with a better safety profile than current antibiotics.
- What could go wrong
- This is an early-phase trial with a small number of patients, so results may not hold up in larger studies. The drug may not be more effective or safer than the existing treatment, and side effects are still being evaluated.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA (HABP) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Jiangsu AOSAIKANG Pharm
RECRUITINGNanjing, Jiangsu, 210000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.